TRH
Respiratory Distress Syndrome
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)protein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Respiratory Distress Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VITAMIN D Prof. Dr. Jörg Leuppi | Phase 3 | BB |
BETAMETHASONE National Center for Research Resources (NCRR) | Phase 3 | BB |
DEXAMETHASONE National Center for Research Resources (NCRR) | Phase 3 | B |
Tocilizumab National Cancer Institute (NCI) | Phase 2 | CCC |
Vasoactive Intestinal Peptide Stony Brook University | Phase 1 | CC |
Molgramostim Savara Inc. | Phase 1 | CC |
Recombinant Human Keratinocyte Growth Factor-2 For Inhalation Shanghai Zhongshan Hospital | Early Phase 1 | C |
Oxygen Evangelismos Hospital | N/A | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →